Furthermore, KLF4 could sensitize the therapeutic response to many known drugs, e.g., cetuximab, cisplatin and mesalazine, in the treatment of cancer (Taracha-Wisniewska et al., 2020), suggesting the combined use of APTO-253 with other anticancer drugs in future clinical trials. This evidence concerns the gene KLF4 and cancer.